Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
Breakthrough T1D has awarded a grant to support the PRISE-hATG clinical study led by Dr. Michael J. Haller, evaluating SAB Biotherapeutics' investigational drug SAB-142 in patients with Stage 3 Type 1 Diabetes beyond the initial 100 days from diagnosis. The study aims to assess whether SAB-142 can preserve beta cell function and modulate immune res…